Status and phase
Conditions
Treatments
About
This is a prospective, randomised double blind, controlled, parallel-group phase I and II study. Its aim is to assess the Evaluation of the intramyocardial injection of autologous bone marrow derived mononuclear stem cells is safe and effective in hear failure patients with reduced left ventricular ejection fraction(<=30%) when compared to a control group of patients undergoing best medical care.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
5 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Peyman Keyhanvar, MD, Ph.D; Nasser Safaie, CTS
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal